Spain devolves drug evaluation
Spain's autonomous regions are to be given a full role in the evaluation of the therapeutic use of new drugs. Jose Martinez Olmos, Secretary General in the Ministry of Health, said that the regions would take part in work carried out by a technical drug evaluation committee and that they would cooperate with the Spanish Drug Agency (AEM).
Mr Olmos added that while technical drug evaluation was not an exclusively government task, the overall drug sector and drug policy remained as a central government function and one which it did not intend to renounce.
He said that by way of improving cohesion in the national health service (SNS) the government was working on the modernization of information systems, with an investment of 240.0 million euros ($287.4 million). This would enable electronic medical prescription and patient data to be extended to the benefit of patients and health care profes-sionals alike.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze